Epigenetics for Drug Discovery
Epigenetics is one of the fastest moving fields in drug discovery, with almost every large pharmaceutical company and a substantial number of biotechnology companies targeting epigenetic processes to treat diseases ranging from cancer to Huntington’s disease and from inflammation to sickle cell anaemia.
The book is structured in three main sections. The first section introduces epigenetics and explain its importance at both a phenomenological and molecular level. The second section goes on to review how each of the big breakthroughs in drug discovery in this field have developed, with a strong emphasis on case histories. The final section highlights the ongoing challenges in creating safe and efficacious epigenetic drugs.
Written and edited by experts within the field from both industry and academia, this book provides an invaluable guide to this developing field for medicinal chemists working in academia and in the pharmaceutical industry.
Epigenetics for Drug Discovery, The Royal Society of Chemistry, 2015.
Download citation file:
Digital access
Print format
Table of contents
-
CHAPTER 1: Epigenetics – What it is and Why it Mattersp1-19ByKarl P. NightingaleKarl P. NightingaleInstitute of Biomedical Research, Birmingham Medical School, University of BirminghamBirmingham B15 2TTUK[email protected]Search for other works by this author on:
-
CHAPTER 2: Enzyme and Protein Families that Regulate Histone Modifications and Crosstalkp20-46ByCharlotte E. Rutledge;Charlotte E. RutledgeSchool of Cancer Sciences, College of Medical and Dental Sciences, University of BirminghamEdgbastonBirmingham B15 2TTUK[email protected]Search for other works by this author on:Bryan M. TurnerBryan M. TurnerSchool of Cancer Sciences, College of Medical and Dental Sciences, University of BirminghamEdgbastonBirmingham B15 2TTUK[email protected]Search for other works by this author on:
-
CHAPTER 3: Epigenetics and Diseasep47-67ByAdele MurrellAdele MurrellCentre for Regenerative Medicine, Department of Biology and Biochemistry, University of BathClaverton DownBath BA2 7AYUK[email protected]Search for other works by this author on:
-
CHAPTER 4: Targeting DNA Methylationp68-95ByMichael McCullarMichael McCullarAstex Pharmaceuticals Inc.4140 Dublin Boulevard, Suite 200DublinCA 94568USASearch for other works by this author on:
-
CHAPTER 5: Targeting Histone Acetylationp96-126ByHella KohlhofHella KohlhofSearch for other works by this author on:
-
CHAPTER 6: Targeting Histone Lysine Methyltransferases in Cancerp127-167ByPatrick TrojerPatrick TrojerSearch for other works by this author on:
-
CHAPTER 7: Targeting Non-Acetylation Histone Erasersp168-191
-
CHAPTER 8: Progress in Targeting Epigenetic Readersp192-229ByChun-wa ChungChun-wa ChungSearch for other works by this author on:
-
CHAPTER 9: Who will Benefit from Epigenetic Drugs?p230-248ByDavid J. ShieldsDavid J. ShieldsSearch for other works by this author on:
-
CHAPTER 10: Dosing – When Less is Morep249-266ByKurinji Pandiyan;Kurinji PandiyanThe Sidney Kimmel Comprehensive Cancer Center1650 Orleans Street, Suite 5401BaltimoreMD 21287USA[email protected]Norris Comprehensive Cancer Center1441 Eastlake AvenueNOR 7341Los AngelesCA 90089USASearch for other works by this author on:Peter A. Jones;Peter A. JonesNorris Comprehensive Cancer Center1441 Eastlake AvenueNOR 7341Los AngelesCA 90089USASearch for other works by this author on:Stephen B. BaylinStephen B. BaylinThe Sidney Kimmel Comprehensive Cancer Center1650 Orleans Street, Suite 5401BaltimoreMD 21287USA[email protected]Search for other works by this author on:
-
CHAPTER 11: Histone Methyltransferase Activity Assaysp267-287ByYuren WangYuren WangSearch for other works by this author on:
-
CHAPTER 12: Safety Considerations for Epigenetic Mechanisms as Drug Targets: Are Existing Toxicology Studies Fit for Purpose?p288-315ByMichael Lawton;Michael LawtonDrug Safety Research and Development, Pfizer Inc.GrotonConnecticutUSASearch for other works by this author on:Robert E. Chapin;Robert E. ChapinDrug Safety Research and Development, Pfizer Inc.GrotonConnecticutUSASearch for other works by this author on:Brett D. Hollingshead;Brett D. HollingsheadDrug Safety Research and Development, Pfizer Inc.AndoverMassachusettsUSASearch for other works by this author on:Karen Leach;Karen LeachCenters for Therapeutic Innovation, Pfizer IncBostonMassachusettsUSASearch for other works by this author on:Prashant R. Nambiar;Prashant R. NambiarDrug Safety Research and Development, Pfizer Inc.AndoverMassachusettsUSASearch for other works by this author on:Mathew Pletcher;Mathew PletcherRare Diseases Research Unit, Pfizer Inc.CambridgeMassachusettsUSASearch for other works by this author on:Amy H. YangAmy H. YangSearch for other works by this author on:
Spotlight
Advertisement
Advertisement